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317Abstracts
UFH with vitamin K antagonist (VKA, e.g. warfarin),
LMWH with VKA, and UFH with LMWH and VKA.
Admissions using the three most common treatments
were compared with respect to length of stay (LOS), med-
ication costs and hospitalization costs. RESULTS: A total
of 953 primary DVT and 3933 primary PE admissions
were identiﬁed. Demographics were comparable for DVT
and PE patients. Most encounters involved treatment
with UFH/VKA (64%), followed by UFH/LMWH/VKA
(14%), and LMWH/VKA (13%). Median (interquartile
range) LOS for DVT patients treated with UFH/VKA,
UFH/LMWH/VKA, and LMWH/VKA were 5 (4–7), 5
(3–7), and 4 (2–6) days, respectively (p < 0.0001); corre-
sponding ﬁgures for PE patients were 6 (5–8), 6 (4–8),
and 5 (3–7) days, respectively (p < 0.0001). Median
(interquartile range) total hospitalization costs for 
DVT admissions were $3059 ($2251–$4306), $3515
($2106–$5351), $2587 ($1776–$3827) respectively (p <
0.0002). Corresponding costs for PE admissions were
$5152 ($3888–$7015), $5668 ($4077–$7928), $4537
($3144–$6168), respectively (p < 0.0001). UFH/LMWH/
VKA treatment was associated with the highest total drug
cost, while UFH/VKA treatment was associated with
lower anticoagulant and total medication costs. Higher
medication costs in the LMWH/VKA group were more
than offset by lower costs in other areas (shorter LOS)
yielding lower overall hospitalization costs. CONCLU-
SIONS: UFH/VKA was the most commonly employed
treatment, and was associated with lower medication
costs as compared to LMWH/VKA. However, LMWH/
VKA treatment was associated with reduced LOS and
lower overall hospitalization costs.
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OBJECTIVES: To compare health service utilization,
costs and outcomes of patients who used dihydropyridine
(DHP) and non-DHP calcium channel blockers (CCB) for
hypertension. METHODS: Utilizing pharmacy, member-
ship and medical data from a large managed care health
plan of over 2 million commercial members, this study
included continuously enrolled patients who had at least
2 or more CCB claims (DHP or non-DHP) between Juny
2000 and June 2001 and did not have a CCB claim 6
months prior to the index claim. Patients were followed
for 12 months after the index prescription and those who
had drug coverage for at least 60% of the days during
the follow-up period were included in the study. Geocod-
ing using national census data was performed to extract
socioeconomic data. Propensity-score matching of DHP
and non-DHP group was performed to adjust for selec-
tion bias. Overall and hypertension-related pharmacy and
medical service utilization and costs, and prevalence of
new renal and vascular-related diagnoses during follow-
up were determined for each study group. RESULTS: A
total of 4443 pairs of propensity-score matched patients
were included in the DHP and non-DHP study group.
Prevalence of new diagnosis for ischemic cerebrovascular
disease was lower in the non-DHP group than in the DHP
group (1.8% vs 2.5%; p < 0.05). Statistically signiﬁcant
difference in prevalence of new diagnosis for renal insuf-
ﬁciency, kidney dialysis, or proteinuria was not observed.
Average hypertension-related pharmacy and medical
costs were signiﬁcantly lower in the non-DHP group
($168 and $260) than in the DHP group ($184 and $370;
p < 0.05). The inter-group difference in costs was larger
among patients who used angiotensin converting enzyme
inhibitors (ACEI) concurrently with CCB. CONCLU-
SION: Treatment of hypertension with non-DHP CCB is
associated with lower prevalence of ischemic cerebrovas-
cular disease and lower pharmacy and medical costs as
compared to DHP CCBs, especially when used concur-
rently with ACEI.
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OBJECTIVE: The LIFE Study demonstrated a signiﬁcant
reduction in cardiovascular morbidity and mortality in
hypertensive patients with ECG left ventricular hyper-
trophy treated with losartan (versus treatment with
atenolol) over a mean period of 4.8 years. This reduction
was essentially related to a signiﬁcant 25% decrease (p =
0.001) in the risk of fatal and non-fatal stroke. The objec-
tive of this study was to compare the treatment costs
relating to each therapeutic strategy throughout the dura-
tion of the LIFE Study. METHODS: Data on efﬁcacy and
resources consumed were extracted from the published
results of the LIFE study. A cost minimization study was
carried out and the costs were calculated from the point
of view of the French healthcare system. The total esti-
mated direct costs included those relating to the medici-
nal product and management of the cardiovascular events
(myocardial infarction, angina pectoris, heart failure,
stroke and revascularization). The medicinal products
were valued on the basis of the purchasing price (retail
price inc. VAT), and hospitalization costs were estimated
on the basis of PMSI data and the national cost scale.
Indirect costs were not considered. RESULTS: Over the
4.8 years, the mean cost of losartan per patient ranged
